

## S. YOUSUF ZAFAR, MD, MHS, FASCO

Duke Cancer Institute  
Hock Pavilion, Suite 602  
2424 Erwin Rd.  
Durham, NC 27710  
Office: 919.684.0138  
Mobile: 919.451.6726  
yousuf.zafar@duke.edu

---

### EDUCATION

<b>AB (Honors)</b> , Sociology, University of Chicago, Chicago, IL	1993-1997
<b>MD</b> , University of Toledo College of Medicine, Toledo, OH	1998-2002
<b>MHS</b> , Duke University, Durham, NC	2007-2009

### POST-GRADUATE TRAINING

<b>Intern and Resident</b> , Department of Medicine University of Cincinnati Medical Center, Cincinnati, OH	2002-2005
<b>Fellow</b> , Hematology and Medical Oncology Duke University Medical Center, Durham, NC	2005-2008
<b>Fellow</b> , Health Services Research and Development Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC	2007-2008

### ACADEMIC APPOINTMENTS

<b>Instructor of Medicine</b> Division of Medical Oncology, Department of Medicine Duke University School of Medicine	2008-2010
<b>Investigator</b> GI Outcomes Research Group, Durham VA Medical Center	2008-2013
<b>Assistant Professor of Medicine, Tenure Track</b> Division of Medical Oncology, Department of Medicine Duke University School of Medicine	2010-2014
<b>Member</b> Duke Cancer Institute	2011-present
<b>Affiliate Faculty</b> Duke Global Health Institute	2011-present
<b>Associate Professor of Medicine, Tenure Track</b> Division of Medical Oncology, Department of Medicine Duke University School of Medicine	2014-2018
<b>Associate Professor of Public Policy, Tenure Track</b> Sanford School of Public Policy, Duke University	2015-2018
<b>Director, Center for Applied Cancer Health Policy</b> Duke Cancer Institute, Duke-Margolis Center for Health Policy	2016-present
<b>Co-Leader, Health Care Delivery Research Program</b> Duke Cancer Institute, Duke-Margolis Center for Health Policy	2016-present
<b>Core Faculty</b> Duke-Margolis Center for Health Policy	2016-present
<b>Clinical Associate Director</b> Duke Forge (Center for Health Data Science)	2017-present
<b>Associate Professor of Medicine with Tenure</b> Division of Medical Oncology, Department of Medicine	2018-present

Duke University School of Medicine <b>Associate Professor of Public Policy with Tenure</b> Sanford School of Public Policy, Duke University	2018-present
<b>Associate Professor of Population Health with Tenure</b> Sanford School of Public Policy, Duke University	2018-present

## CERTIFICATION AND LICENSURE

North Carolina State Medical License	2005
Diplomate, American Board of Internal Medicine	2005
Diplomate, Subspecialty Medical Oncology	2009

## PUBLICATIONS

### *Peer-reviewed original research*

1. **Zafar SY**, Abernethy AP, Abbott DH, Grambow SC, Marcello JE, Herndon JE, 2nd, Rowe KL, Kolimaga JT, Zullig LL, Patwardhan MB, Provenzale DT. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. *BMC Cancer*. 2008;8:345. DOI: 10.1186/1471-2407-8-345. PMID: 2613913.
2. Abernethy AP, Barbour SY, Uronis H, **Zafar SY**, Coan A, Rowe K, Pupa MR, Wheeler JL, Herndon JE, 2nd. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. *Support Care Cancer*. 2009;17:735-744. DOI: 10.1007/s00520-008-0562-6.
3. Dupont A, Wheeler J, Herndon JE, 2nd, Coan A, **Zafar SY**, Hood L, Patwardhan M, Shaw HS, Lysterly HK, Abernethy AP. Use of tablet personal computers for sensitive patient-reported information. *J Support Oncol*. 2009;7:91-97.
4. **Zafar SY**, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, Abernethy AP. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. *J Oncol Pract*. 2009;5:228-233. DOI: 10.1200/jop.091010. PMID: 2790671.
5. Abernethy AP, **Zafar SY**, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE, 2nd. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. *J Pain Symptom Manage*. 2010;40:545-558. DOI: 10.1016/j.jpainsymman.2010.01.017.
6. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, **Zafar SY**, Fletcher RH. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. *J Clin Oncol*. 2010;28:620-627. DOI: 10.1200/jco.2009.23.8485. PMID: 2815997.
7. Jackson GL, Melton LD, Abbott DH, Zullig LL, Ordin DL, Grambow SC, Hamilton NS, **Zafar SY**, Gellad ZF, Kelley MJ, Provenzale D. Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. *J Clin Oncol*. 2010;28:3176-3181. DOI: 10.1200/jco.2009.26.7948. PMID: 2903314.
8. **Zafar SY**, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, 2nd, Abernethy AP. Treatment-related toxicity and supportive care in metastatic colorectal cancer. *J Support Oncol*. 2010;8:15-20. DOI.
9. Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, **Zafar SY**, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. *Oncologist*. 2011;16:1131-1137. DOI: 10.1634/theoncologist.2011-0078.

10. Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, **Zafar SY**, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). *Cancer Chemother Pharmacol*. 2011;67:465-474. DOI: 10.1007/s00280-010-1507-6.
11. Palta M, Patel P, Broadwater G, Willett C, Pepek J, Tyler D, **Zafar SY**, Uronis H, Hurwitz H, White R, Czito B. Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy. *Ann Surg Oncol*. 2011. DOI: 10.1245/s10434-011-2117-1.
12. Phelan SM, Griffin JM, Jackson GL, **Zafar SY**, Hellerstedt W, Stahre M, Nelson D, Zullig LL, Burgess DJ, van Ryn M. Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. *Psychooncology*. 2011. DOI: 10.1002/pon.2048.
13. **Zafar SY**, Malin JL, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. *BMC Cancer*. 2011;11:354. DOI: 10.1186/1471-2407-11-354. PMID: 3174931.
14. Currow DC, Tieman JJ, Greene A, **Zafar SY**, Wheeler JL, Abernethy AP. Refining a Checklist for Reporting Patient Populations and Service Characteristics in Hospice and Palliative Care Research. *J Pain Symptom Manage*. 2012. DOI: 10.1016/j.jpainsymman.2011.05.015
15. Strickler J, Starodub A, Jia J, Meadows K, Nixon A, Dellinger A, Morse M, Uronis H, Marcom PK, **Zafar SY**, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. *Cancer Chemotherapy and Pharmacology*. 2012;70:251-258. DOI: 10.1007/s00280-012-1911-1.
16. Vlahovic G, Meadows K, Uronis H, Morse M, Blobe G, Riedel R, **Zafar SY**, Alvarez-Secord A, Gockerman J, Starodub A, Ready N, Anderson E, Bendell J, Hurwitz H. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. *Cancer Chemother Pharm*. 2012;70:95-102. DOI: 10.1007/s00280-012-1889-8.
17. **Zafar SY**, Currow DC, Cherny N, Strasser F, Fowler R, Abernethy AP. Consensus-based standards for best supportive care in clinical trials in advanced cancer. *Lancet Oncol*. 2012;13:e77-82. DOI: 10.1016/s1470-2045(11)70215-7.
18. **Zafar SY**, Malin JL, Grambow SC, Abbott DH, Kolimaga JT, Zullig LL, Weeks JC, Ayanian JZ, Kahn KL, Ganz PA, Catalano PJ, West DW, Provenzale D, for the Cancer Care Outcomes Research and Surveillance Consortium. Chemotherapy use and patient treatment preferences in advanced colorectal cancer. *Cancer*. 2012;119:854-862. DOI: 10.1002/cncr.27815. PMID: 22972673
19. Fouad MN, Lee JY, Catalano PJ, Vogt TM, **Zafar SY**, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CI. 2012. Enrollment of patients with lung and colorectal cancer patients in clinical trials. *J Oncol Pract* 2012;9e40-e47. doi:10.1200/JOP.2012.000598
20. Zullig LL, Muiruri C, Abernethy A, Weiner BJ, Bartlett JA, Onoko O, **Zafar SY**. Cancer Registration Needs Assessment at a Tertiary Medical Center in Kilimanjaro, Tanzania. *World Health Population* 2013.14:12-23.
21. **Zafar SY**, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. *Oncologist* 2013;18:281-390. PMID: 23442307
22. Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, **Zafar SY**, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. *Oncologist*. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404.
23. Jackson GL, Zullig LL, **Zafar SY**, Powell AA, Ordin DL, Gellad ZF, Abbott DH, Schlosser JM, Hersh J, Provenzale D. 2010. Utilizing NCCN Practice Guidelines to Measure the Quality of

- Colorectal Cancer Care in the Veterans Health Administration. *J Nat Comp Cancer Network* 2013;11:431-441
24. Bartley AN, Hamilton SR, Alsabeh R, Ambinder EP, Berman M, Collins E, Fitzgibbons PL, Gress, DM, Nowak JA, Samowitz WS, **Zafar SY**. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. *Arch Pathol Lab Med* 2013. doi: 10.5858/arpa.2013-0231-CP. Epub 2013 Jun 28.
  25. Zullig LL, Vanderburg SB, Muiruri C, Abernethy A, Weiner BJ, Bartlett JA, Oneko O, Lisasi E, Oresto M, **Zafar SY**. Sustainability of cancer registration in the Kilimanjaro region of Tanzania - a qualitative assessment. *World Health Population*. 2013;14(2):12-23.
  26. Zullig LL, Peppercorn J, Schrag D, Taylor D, Lu Y, Samsa G, Abernethy AP, **Zafar SY**. Financial distress, utilization of cost-coping strategies, and adherence to prescription medication among cancer patients. *J Onc Pract* 2013. Epub Aug 20, 2013.
  27. Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, **Zafar SY**, Hurwitz HI. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. *Invest New Drugs*. 2014;32:330-339.
  28. Van Ryn M, Phelan S, Arora NK, Haggstrom D, Jackson GL, **Zafar SY**, Griffin JM, Zullig LL, Provenzale D, Yeazel MW, Jindal RM, Clauser SB. Patient-reported quality of symptom management among colorectal cancer patients in the VA. *J Clin Oncol* 2014;10:809-815.
  29. Chino F, Peppercorn J, Taylor DH, Lu Y, Samsa G, Abernethy AP, **Zafar SY**. Self-reported financial burden and satisfaction with care among patients with cancer. *Oncologist* 2014; 2014;19:414-420.
  30. Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, **Zafar SY**, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. *Invest New Drugs* 2014;32:700-709. PMID: 24711126
  31. Smith SK, Nicolla J, **Zafar SY**. Bridging the gap between cancer patient financial distress and available resources: A qualitative study. *J Oncol Pract* 2014;10:e368-372 PMID: 24865219
  32. Bestvina C, Zullig L, Rushing C, Chino F, Samsa G, Altomare I, Tulskey J, Ubel P, Schrag D, Nicolla J, Abernethy A, Peppercorn J, **Zafar SY**. Patient-oncologist cost communication, financial distress, and medication adherence. *J Oncol Pract* 2014;10:162-167. PMID: 24839274
  33. De Boer C, Niyonzima N, Orem J, Bartlett J, **Zafar SY**. Prognosis and delay of diagnosis among Kaposi's sarcoma patients in Uganda: a cross-sectional study. *Infect Agent Cancer*. 2014;20:17 eCollection. PMID: 24904686
  34. Taylor DH, Danis M, **Zafar SY**, Howie LJ, Samsa GP, Wolf SP, Abernethy AP. There is a mismatch between Medicare's benefit package and the preferences of patients with cancer and their caregivers. *J Clin Oncol*. 2014;32:3163-2168.
  35. Irwin BB, **Zafar SY**, Atomare I, Kimmick GG, Marcom KP, Houck K, Peppercorn JP. Patient experience and attitudes towards addressing the cost of breast cancer care. *Oncologist*. 2014 19(11):1135-40.
  36. Danis M, Abernethy AP, **Zafar SY**, Samsa GP, Wolf SP, Howie L, Taylor DH. A decision exercise to engage cancer patients and families in deliberation about Medicare coverage for advanced cancer care. *BMC Health Serv Res*. 2014;14:315.
  37. **Zafar SY**, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. *J Oncol Pract*. 2015;11:145-150.
  38. Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf, S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, **Zafar**

- SY**, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KW, von Gunten CF, Abernethy AP. Safety and benefit of discontinuing statin medications in the setting of advanced life-limiting illness. *JAMA Int Med*. 2015;doi: 10.1001/jamainternmed.2015.0289 [Epub ahead of print]
39. **Zafar SY**, Chino F, Ubel PA, Rushing C, Samsa G, Altomare I, Schrag D, Tulskey JA, Abernethy AP, Peppercorn JP. The utility of cost discussions between cancer patients and oncologists. *Am J Manage Care* 2015;21:607-615
  40. Nipp RD, Zullig LL, Samsa G, Peppercorn JM, Schrag D, Taylor DH, Abernethy AP, **Zafar SY**. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. *Psycho-Oncol* 2015; doi: 10.1002/pon.3911. [Epub ahead of print]
  41. Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, **Zafar SY**, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KAA, Armstrong PW, Ohman EM, for the TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. *Eur Heart J* 2016;37:412-22.
  42. Altomare I, Irwin B, Houck K, **Zafar SY**, Maloney B, Greenup R, Peppercorn J. Physician experience and attitudes toward addressing the cost of cancer care. *J Onc Pract* 2016; 12:247-8
  43. Hochman MJ, Wolf S, **Zafar SY**, Portman D, Bull J, Kamal AH. Comparing unmet needs to optimize quality: Characterizing inpatient and outpatient palliative care populations. *J Pain Symptom Manage* 2016; doi: 10.1016/j.jpainsymman.2015.12.338. [Epub ahead of print]
  44. Lathan CS, Cronin A, Tucker-Seeley R, **Zafar SY**, Ayanian J, Schrag D. The association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. *J Clin Oncol* 2016;34:1732-1740.
  45. Zullig LL, Vlastelica L, Shankaran V, Wolf S, **Zafar SY**. The role of patient financial assistance programs (PAPs) in reducing costs for cancer patients. *J Manage Care Specialty Pharm* 2016;23:407-411.
  46. Mowery YM, Salama JK, **Zafar SY**, Moore HG, Willett CG, Czito BG, Hopkins MB, Palta M. Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiation therapy by radiation oncologists in the US. *Cancer* 2017;15:1434-1441.
  47. **Zafar SY**, Peppercorn J, Asabere A, Bastian A. Transparency of industry-sponsored oncology patient financial assistance programs using a patient-centered approach. *J Oncol Pract* 2017;13:e240-e248.
  48. Porter LS, Keefe FJ, Baucom DH, Olsen M, **Zafar SY**, Uronis H. A randomized pilot trial of a videoconference couples communication intervention for advanced GI cancer. *Psychooncology* 2017; 26:1027-1035.
  49. Hunter, W, **Zafar SY**, Hesson A, David JK, Kirby C, Barnett JA, Ubel PA. Discussing Healthcare Expenses in the Oncology Clinic: Analysis of Cost Conversations in 677 Outpatient Encounters. *J Oncol Pract* 2017;13:e944-e956.
  50. Chino F, Peppercorn JM, Rushing C, Kamal AH, Altomare I, Samsa G, **Zafar SY**. Out-of-pocket costs, financial distress, and underinsurance in cancer care. *JAMA Onc* 2017;3:1582-1584.
  51. Houts AC, Ogale S, **Zafar Y**, Hubbard JH, Satram-Hoang S, Sommer N, Walker MS. Progression Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. *J Gastrointest Canc* 2017 [In press]
  52. Chino F, Suneja G, Moss H, **Zafar SY**, Havrilesky L, Chino J. Healthcare disparities in cancer patients receiving radiation: Changes in insurance status after Medicaid expansion under the Affordable Care Act. *Int J Radiation Onc Bio Phys* 2018; 1;101(1):9-20.

53. Moss H, Havrilesky LJ, Suneja G, **Zafar SY**, Chino J. Trends in insurance status among patients diagnosed with cancer before and after implementation of the Affordable Care Act. *J Oncol Pract* 2018 [In press]
54. Zullig LL, Ramos K, Berkowitz C, Miller JJ, Dolor RJ, Koontz BF, **Zafar SY**, Allen DH, Tenhover JA, Bosworth HB. Assessing key stakeholders' knowledge, needs, and preferences for head and neck cancer survivorship care plans. *J Cancer Educ* 2018 [In press]
55. Boucher NA, Nicolla J, Ogunseitani A, Kessler ER, Ritchie C, **Zafar SY**. Feasibility and acceptability of a best supportive care (BSC) checklist among clinicians. *J Pall Med*. 2018 [epub ahead of print]
56. Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, **Zafar SY**, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. *Oncologist* 2018. [epub ahead of print]
57. Hastert T, Young G, Pennell M, Padamsee T, **Zafar SY**, DeGraffinreid C, Naughton M, Simon M, Paskett E. Predictors of financial burden in cancer survivors: Results from the LILAC Study. *Cancer Med* 2018 [In press]
58. Chino F, Peppercorn J, Rushing C, Nicolla J, Kamal AH, Altomare I, Samsa G, **Zafar SY**. "Going for Broke": A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care. *J Onc Pract* 2018 [In press]
59. Chino F, Kamal AH, Leblanc TW, **Zafar SY**, Suneja G, Chino J. Place of Death for Cancer Patients in the United States, 1999-2015: Racial, Age, and Geographic Disparities. *Cancer* 2018 [In press]
60. Langer SL, Romano JM, Todd MW, Strauman TJ, Keefe FJ, Syrjala KL, Bricker JB, Ghosh N, Burns JB, Bolger N, Puleo BK, Gralow JR, Shankaran V, Westbrook KE, **Zafar SY**, Porter LS. Links between Communication and Relationship Satisfaction among Patients with Cancer and their Spouses: Results of a Fourteen-day Smartphone-based Ecological Momentary Assessment Study. *Frontiers Psych* 2019 [In press]

### **Peer-Reviewed Review Articles**

61. **Zafar Y**, Jazieh AR. Lipomatous hypertrophy of the interatrial septum evidenced on positron emission tomography in a patient with thyroid cancer. *Am J Clin Oncol*. 2006;29:418-419. DOI: 10.1097/01.coc.0000170585.91248.b8.
62. **Zafar SY**, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. *Oncologist*. 2008;13:769-778. DOI: 10.1634/theoncologist.2007-0251.
63. Abernethy AP, Wheeler JL, **Zafar SY**. Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach. *Curr Opin Support Palliat Care*. 2009;3:41-49. DOI: 10.1097/SPC.0b013e32832531ce.
64. Cherny NI, Abernethy AP, Strasser F, Sapir R, Currow D, **Zafar SY**. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. *J Clin Oncol*. 2009;27:5476-5486. DOI: 10.1200/jco.2009.21.9592.
65. **Zafar SY**, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. *Support Care Cancer*. 2009;17:117-127. DOI: 10.1007/s00520-008-0505-2.
66. Abernethy AP, Ahmad A, **Zafar SY**, Wheeler JL, Reese JB, Lyerly HK. Electronic patient-reported data capture as a foundation of rapid learning cancer care. *Med Care*. 2010;48:S32-38. DOI: 10.1097/MLR.0b013e3181db53a4.
67. Abernethy AP, Aziz NM, Basch E, Bull J, Cleeland CS, Currow DC, Fairclough D, Hanson L, Hauser J, Ko D, Lloyd L, Morrison RS, Otis-Green S, Pantilat S, Portenoy RK, Ritchie C,

- Rocker G, Wheeler JL, **Zafar SY**, Kutner JS. A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. *J Palliat Med*. 2010;13:1407-1413. DOI: 10.1089/jpm.2010.0261.
68. Abernethy AP, Wheeler JL, **Zafar SY**. Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model. *Curr Opin Support Palliat Care*. 2010;4:36-45. DOI: 10.1097/SPC.0b013e32833575fd. PMID: 2871247.
69. Bull J, **Zafar SY**, Wheeler JL, Harker M, Gblokpor A, Hanson L, Hulihan D, Nugent R, Morris J, Abernethy AP. Establishing a regional, multisite database for quality improvement and service planning in community-based palliative care and hospice. *J Palliat Med*. 2010;13:1013-1020. DOI: 10.1089/jpm.2010.0017.
70. **Zafar SY**, Currow DC, Daugherty CK, Abernethy AP. Standards for palliative care delivery in oncology settings. *Cancer J*. 2010;16:436-443. DOI: 10.1097/PPO.0b13e3181f289f7.
71. Hirsch BR, **Zafar SY**. Capecitabine in the management of colorectal cancer. *Cancer Manag Res*. 2011;3:79-89. DOI: 10.2147/cmr.s11250. PMID: 3097797.
72. Rangwala F, **Zafar SY**, Abernethy AP. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. *Curr Opin Support Palliat Care*. 2012;6:69-76. DOI: 10.1097/SPC.0b013e32834f689d.
73. Hirsch BR, **Zafar SY**. Comparative effectiveness research: Moving medical oncology forward. *Sem Radiat Oncol*. 2014;24:49-53.
74. Peppercorn JM, **Zafar SY**, Houck K, Ubel PA, Meropol NJ. Does comparative effectiveness research promote rationing of cancer care? *Lancet Oncol* 2014;15:e132-e138.
75. Bestvina CM, Zullig LL, **Zafar SY**. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. *Future Onc*. 2014;10:2189-2199.
76. Nipp R, Currow D, Cherny N, Strasser F, Abernethy AP, **Zafar SY**. Best supportive care in clinical trials: Review of the inconsistency in control arm design. *Br J Cancer*. 2015;113:6-11.
77. Kasi PM, **Zafar SY**, Grothey A. Is obesity an advantage in colorectal cancer patients? *Ex Rev Gastroenterology Hepatology* 2015;14:1-4. [Epub ahead of print]
78. Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, **Zafar SY**, Shankaran V, de Souza J, Wong YN. The parity paradigm: can legislation help reduce the cost burden of oral anticancer medications? *Value Health*. 2016;19:88-98.
79. **Zafar SY**, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB. How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. *Am Soc Clin Oncol Educ Book*. 2017;37:35-39.
80. Sitlinger A, **Zafar SY**. Beyond morbidity and mortality: Outcomes that matter to patients. *Surg Oncol Clin N Am*. 2018 [In press]

### **Peer-Reviewed Editorials, Commentaries, and Letters**

81. **Zafar Y**, Hurwitz, HI. The Burtness article reviewed: Monoclonal antibodies to EGFR: What does the future hold? *Oncology (Williston Park)* 21:976-977, 2007.
82. **Zafar SY**, Currow D, Abernethy AP. Defining best supportive care (Letter). *J Clin Oncol* 2008. 26:5139-5140. PMID: 18838696.
83. Currow DC, Foley K, **Zafar SY**, Wheeler JL, Abernethy AP. The need for a re-evaluation of best supportive care studies reported to date. *Br J Cancer* 2011.104:390-391. PMID: 21285970.
84. **Zafar SY**, Abernethy AP. Financial Toxicity, Part I: A New Name for a Growing Problem. *Oncology (Williston Park)*. 2013;27(2):80-1
85. **Zafar SY**, Abernethy AP. Financial Toxicity, Part II: How can we help with the burden of treatment-related costs? *Oncology (Williston Park)*. 2013;27(4):253-254, 256. PMID: 23781687

86. Ubel PA, Abernethy AP, **Zafar SY**. Full Disclosure — Out-of-Pocket Costs as Side Effects. *New Eng J Med* 2013;369:1484-1486.
87. **Zafar SY**, Tulsy JA, Abernethy AP. It's time to have "the talk": cost communication and patient-centered care. *Oncology* 2014;28:479-480.
88. Deming D, Uboha N, **Zafar SY**, Rosenberg S, Bassetti M, Glasgow S, Lubner S. Adjuvant chemotherapy for Stage II rectal cancer. *Semin Oncol*. [In press]
89. **Zafar SY**, Ubel PA, Tulsy JA, Pollak KI. Cost-related health literacy: A key component of high quality cancer care. *J Oncol Pract* 2015;11:171-173.
90. **Zafar SY**. Financial toxicity of cancer care: It's time to intervene. *J Nat Cancer Inst*; 2016;108.
91. Wollins D, **Zafar SY**. A touchy subject: Can physicians improve value by discussing costs and clinical benefits with patients? *Oncologist* 2016; 21:1157-1160.
92. **Zafar SY**, Peppercorn JM. Patient financial assistance programs: A path to affordability or a barrier to accessible cancer care? *J Clin Oncol* 2017; 35:2113-2116.
93. Sitlinger AP, **Zafar SY**. With colorectal cancer treatment, physical toxicity is not the only concern. *Dis Colon Rectum*. 2018;61:4-5.
94. Sloan C, **Zafar SY**. Ask early and ask often: How discussing costs could save your patient's life. *NC Med J* 2018 [In press]
95. Tina Shih YC, Fuld Nasso S, **Zafar SY**. Price transparency for whom? In search of out-of-pocket cost estimates to facilitate cost communication. *Pharmacoeconomics* 2018;36(3):259-261.
96. Tran G, **Zafar SY**. Price of cancer care and its tax on quality of life. *J Oncol Pract* 2018;14(2):69-71.
97. Chan RJ, Gordon L, **Zafar SY**, Miaskowski C. Financial toxicity and symptom burden: what is the big deal? *Supp Care Cancer* 2018 [In press]
98. Leopold C, Peppercorn JM, **Zafar SY**, Wagner AK. Defining Value of Cancer Therapeutics-A Health System Perspective. *J Natl Cancer Inst* 2018. [Epub ahead of print]
99. **Zafar SY**, Polite B, McCurry M. Engaging patients in value-based cancer care: A missed opportunity. *JAMA Oncol* 2018 [In press]

### **Book Chapters**

100. **Zafar SY**, Blobe G. Chapter 31: Lower Gastrointestinal Cancer: Colon, rectum, anal. *Oxford American Handbook of Oncology*. May 2009.
101. **Zafar SY**, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB. "How should we intervene on the financial toxicity of cancer care?: One shot, four perspectives" *ASCO Annual Meeting Educational Book*, 2017;37:35-39.
102. Carrera P, **Zafar SY**. "Financial toxicity." *The MASCC Textbook of Cancer Supportive Care and Survivorship, Second Edition*, Springer. 2018:127-143

### **Online commentary**

1. **Zafar Y**, Abernethy AP. The need for health care reform: cancer care cost and the patient perspective. *Kaiser Health News*. 2011. <http://bit.ly/1aK1wNx>
2. **Zafar SY**. "Preparing Patients for Toxicity—Physical and Financial" *ASCO Connection*. 2013. <http://bit.ly/161t8IR>
3. **Zafar SY**. "Answering Your Patients' Question: 'What did you learn at the Meeting?'" *ASCO Connection*. 2013. <http://bit.ly/161t8IR>
4. **Zafar SY**. "'I'm not a doctor, but I play one on TV:'" What's the benefit of direct-to-consumer advertising?" *ASCO Connection*. 2013. <http://bit.ly/1k8niGS>
5. **Zafar SY**. "Looking for value in cancer care? Start here." *ASCO Connection*. 2015. <http://bit.ly/1FRPjWd>

6. **Twitter:** @yzafar. Over 4500 international followers. "Verified" by Twitter, status reserved for a select few with accounts of public interest. Ongoing commentary on topics related to cost and value in cancer care, and gastrointestinal oncology.

## PROFESSIONAL MEMBERSHIPS

American Society of Clinical Oncology	2005-present
North Carolina Oncology Association	2008-present
Alliance for Clinical Trials in Oncology (formerly CALGB)	2008-present
Association for Clinical and Translational Science	2012-present
Palliative Care Research Cooperative	2010-present

## HONORS AND AWARDS

Honors in the College, Honors in the Department of Sociology, University of Chicago	1997
American Society of Hematology Medical Student Research Fellowship	1999
University of Cincinnati Resident Scholar Program	2004
American Society of Clinical Oncology/sanofi-aventis National Meeting Travel Grant	2007
Duke Comprehensive Cancer Center Young Investigator Award	2008
CALGB Foundation Investigator Award	2009
HealthWell Foundation Career Development Award	2009
American Cancer Society Mentored Research Scholar Grant	2011
Duke Cancer Institute Cancer Control Pilot Award	2012
Duke KM1 Comparative Effectiveness Research Career Development Award	2013
Duke Cancer Institute Pilot Award	2013
Duke Medical Oncology Annual Education Award	2014
William Kane Hematology/Oncology Teaching Award	2015
Alpha Omega Alpha Medical Honor Society	2017
Fellow, American Society of Clinical Oncology	2018

## GRANTS

Agency for Healthcare Research and Quality and Health Services Research and Development Training Grant (T32); Role: Fellow	2007-2008
Agency for Healthcare Research and Quality R01 (1R01HS018360-01; PI: Taylor); Role: Co-investigator	2009-2010
Duke Mentored Clinical Research Scholar Program Career Development Award (5KL2RR024127-03); Role: Investigator	2009-2011
CALGB Foundation Investigator Award; Role: PI	2009-2011
HealthWell Foundation Career Development Award; Role: PI	2009-2011
American Cancer Society Mentored Research Scholar Grant (121276-MRSG-11-171-01-PCSM); Role: PI	2011-2016
Duke Cancer Institute Cancer Control Pilot Award; Role: PI	2012-2013
American Cancer Society Grant (PI: Porter); Role: Co-investigator	2012-2014
Duke KM1 Comparative Effectiveness Research Career Development Award	2013-2014
Duke Cancer Institute Pilot Award; Role: PI	2013-2014

Duke Global Health Institute/Duke Cancer Institute Pilot Award (PI: Zullig); Role: Co-I	2015-present
Duke Cancer Institute Cancer Control Pilot Award; Role: Co-I (PI: Zullig)	2016-present
National Cancer Institute R42 (STTR) 1R42CA210699-01; Role: PI	2016-present
Duke Institute of Health Innovation "Innovation Award"; Role: Co-I	2017-2018

## **ORGANIZATIONAL ACTIVITIES**

### ***Institutional***

Fellowship Program Committee, Division of Hematology and Oncology, Duke University Medical Center	2012-present
Institutional Review Board, Duke University Medical Center	2012-2016
Cancer Protocol Committee, Duke Cancer Institute	2012-present
Global Cancer Research Working Group, Duke Global Health Institute	2011-2016
Executive Committee, Duke Crush Colorectal Cancer 5K Run/Walk	2013-2016
Focus Area Co-Leader, Healthcare Delivery Research; Cancer Control and Population Sciences Program, Duke Cancer Institute	2014-present
School of Medicine Standing Committee on Misconduct in Research	2016-present

### ***National Activities and Professional Societies***

Veterans Administration Health Services Merit Grant Review Committee	2008
Health Outcomes Committee, Alliance for Clinical Trials in Oncology	2008-2016
Clinical Practice Guidelines Committee, American Society of Clinical Oncology	2010-2013
Web Design Working Group, American Society of Clinical Oncology	2011-2013
Ancillary Studies Workgroup, American Society of Clinical Oncology/College of American Pathologists	2012-2013
Health Disparities Committee, Alliance for Clinical Trials in Oncology	2012-2017
Health Disparities Committee, American Society of Clinical Oncology	2013-2016
Supportive Care Guideline Advisory Group, American Society of Clinical Oncology	2013-2015
Faculty, American Society of Clinical Oncology (ASCO) University, "Disparities in Cancer Care"	2013-present
Member, American Society of Clinical Oncology (ASCO) Annual Quality Symposium Planning Committee	2014-2017
Association of Community Cancer Centers Financial Advocacy Network Advisory Committee	2015-2016, 2018-present
ASCO-Cancer Support Community Work Group for Value, Advisory Board	2015-2016
American Cancer Society Health Policy/Health Services Peer Review Cmte	2015-present
Member, ASCO Cancer Education Committee	2016-present
Cancer Care Delivery Research Cmte, Alliance for Clinical Trials in Oncology	2015-present
Member, ASCO Social Media Working Group	2017-present
Member, ASCO Government Relations Committee	2017-present
Member, ASCO Value Taskforce	2018-present

### ***National Boards***

Vivor, LLC; Advisory Board	2015-present
Family Reach Foundation; Medical Advisory Board	2015-2017
Family Reach Foundation; Board of Directors	2017-present

Sam Fund; Advisory Board	2017-present
Copernicus Group Institutional Review Board; Board Member	2017-present
AIM Specialty Health; Oncology Pathway Advisory Board	2017-present
Association of Community Cancer Centers; Financial Advisory Network Advisory Committee	2018-present

## EDUCATIONAL ACTIVITIES

### *Extramural Invited Oral Presentations - International*

"Research to practice." KCMC Clinical Oncology Symposium, Moshi, Tanzania	2011
"How do we define a high-quality cancer registry?" KCMC Clinical Oncology Symposium, Moshi, Tanzania	2012
"Treatment of esophagogastric cancer." Department of Surgery, Kilimanjaro Christian Medical Center, Moshi, Tanzania	2012
"Treatment of colorectal cancer." Department of Surgery, Kilimanjaro Christian Medical Center, Moshi, Tanzania	2012
"Financial burden and medical decision making: Does cost matter?" Duke-National University of Singapore Graduate Medical School, Singapore	2013
"Do comparative and cost-effectiveness studies lead to rational use or rationing of cancer services?" Oncology at the Limits 2014, Heidelberg, Germany	2014
"Survival outcomes according to body mass index: results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer" ESMO World Congress on Gastrointestinal Cancer 2015, Barcelona, Spain	2015
"Financial impact of novel cancer therapeutics." International Forum for Quality Caner Care - Cancer Care Commission 2016, Dubai, UAE	2016

### *Extramural Invited Oral Presentations - National*

"Room for improvement: Delivering quality care in colorectal cancer." Veterans Administration Colorectal Cancer Care Collaborative. San Antonio, TX	2007
"Timeliness of colorectal cancer care." Veterans Administration Colorectal Cancer Care Collaborative. Las Vegas, NV	2007
"Cost of care and the cancer experience." HealthWell Foundation Board of Directors Meeting	2011
"Impact of out-of-pocket expenses on cancer care." American Society of Clinical Oncology Annual Meeting.	2011
"The financial toxicity of cancer care: How do costs impact the cancer patient's experience?" Ovarian Cancer in Women of African Ancestry (OCWAA) Consortia Meeting, National Institutes of Health, Bethesda, MD	2013
"Financial toxicity of cancer care." CBI's 10th Forum on Patient Reported Outcomes. Philadelphia, PA.	2013
"Financial distress, communication, and cancer treatment decision-making: Does cost matter?" American Society of Clinical Oncology Annual Meeting, Chicago, IL	2013

“Financial implications in the management of GI cancers: Does cost matter?” International Society of Gastrointestinal Oncology Conference, Washington, DC	2013
“Financial toxicity Part I: A new name for a growing problem” Association of Community Cancer Centers Annual Pre-Meeting, Boston, MA	2013
“Financial toxicity Part II: How can we help with the burden of treatment- related costs?” Association of Community Cancer Centers Annual Pre- Meeting, Boston, MA	2013
“Hot topics in metastatic colorectal cancer,” Peninsula Regional Medical Center, Salisbury, MD	2013
“Shared decision-making and financial burden: The ethics of talking costs” Oncology Nursing Society Connections Conference, Dallas, TX	2013
“Hot topics in metastatic colorectal cancer,” Rush Medical Center, Chicago, IL	2014
“The financial toxicity of cancer treatment: Can patients cope with costs?” The Institute of Medicine, National Cancer Policy Forum, Washington, DC	2014
“The Elephant in the Room: How Does Financial Toxicity Impact Cancer Care Quality?” ASCO Quality Symposium, Boston, MA	2014
“Intervening on financial toxicity” Alliance for Clinical Trials Fall Group Meeting, Chicago, IL	2014
“Financial Toxicity: How the cost of cancer care impacts our patients” American Society of Hematology Annual Meeting, Special Symposium on Quality, San Francisco, CA	2014
“The side effect physicians aren’t discussing: Financial toxicity” The Advisory Board Company, National Webinar	2014
“Addressing the Elephant in the Room: How Can We Reduce Our Patients’ Financial Burden?” Health Policy and Oncology Seminar, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA	2014
“Financial Toxicity: How Can We Help Our Patients?” Association of Community Cancer Centers Annual Meeting, Washington, DC	2015
“The elephant in the room: How high cost is harming cancer care” Distinguished Speaker, Cancer Prevention and Control Colloquia Series, National Cancer Institute, Rockville, MD	2015
“Going for Broke: Cancer and Personal Finances” Clinical Science Symposium, American Society of Clinical Oncology Annual Meeting, Chicago, IL	2015
“Helping patients with financial toxicity” ACCC Financial Advocacy Network Meeting, Burlingame, CA	2015
“Quality and value in cancer care.” ASCO Quality Training Program, Washington, DC	2015
“The value proposition in oncology.” Best of ASCO, Chicago, IL	2015
“Shared Decision-Making Related to Immunotherapies: Targeting, Communication, and Cost.” Moderator, NCCS Cancer Policy Roundtable, Washington, DC	2015
“Intervening on the financial toxicity of cancer care.” Eighth AACR Conference on The Science of Cancer Health Disparities, Atlanta, GA	2015
“How do patients define value in cancer care?” 4 <sup>th</sup> Annual AJMC Meeting on Patient-Centered Oncology Care, Baltimore, MD	2015
“Value in oncology: Patients, providers, and politics.” Yale Cancer Center Oncology Grand Rounds, New Haven, CT	2015
“Value in oncology: Patients, providers, and politics.” Memorial Sloan-Kettering Center for Health Policy and Outcomes Seminar, New York, NY	2016

“Diagnosis and treatment: Treating patients and managing their expectations” Genentech Oncology Institute, San Francisco, CA	2016
“Patient education and Navigation: Addressing and tackling coverage knowledge gaps.” Panelist, 17th Annual Patient Assistance and Access Programs Conference, Baltimore, MD	2016
“The Finances of Cancer Care: Patient Experiences and Attitudes.” American Society of Clinical Oncology Annual Meeting, Chicago, IL.	2016
“Intervening on financial toxicity: What can we do today?” Bladder Cancer Think Tank, Denver, CO	2016
“Financial toxicity and quality care.” Global Palliative Care Quality Alliance Virtual Conference	2016
“Financial toxicity of cancer treatment.” First Annual National Cancer Institute Cancer Health Disparities Research Symposium, Bethesda, MD	2016
“The value proposition in oncology” Dartmouth-Norris Comprehensive Cancer Center Annual Retreat, Hanover, NH	2016
“The value proposition in oncology.” Brown University, Hematology-Oncology Grand Rounds, Providence, RI	2017
“The financial toxicity of cancer care.” Oncology Nurse Advisor National Navigation Summit, Austin, TX	2017
“Communicating cancer costs with patients.” CMS Oncology Care Model Practice Redesign National Webinar, online live presentation	2017
“Communicating cancer costs with patients.” Alliance for Clinical Trials NCORP Seminar on Financial Toxicity, online live presentation	2017
“Patient engagement in cancer care today.” Keynote address, Cancer Support Community Research and Training Institute, Philadelphia, PA	2017
“The financial toxicity of cancer care.” Northern New England Clinical Oncology Society Annual Meeting, Stowe, VT	2017
“Paying for cancer care: Will Washington change the rules?” American Association of Cancer Institutes Annual Meeting, Washington, DC	2017
“Benefit design and patient perspective” Duke-Margolis Center workshop on value-based reimbursement of oncology, Washington, DC	2017
“Can we afford to avoid the cost discussion?” University of Wisconsin-Madison Annual Bioethics Symposium, Madison, WI	2018
“Intervening on financial toxicity” NRG Oncology Cooperative Group National Meeting, Philadelphia, PA	2018
“Do patients want to discuss costs with their oncologists?” ASCO Annual Meeting, Chicago, IL	2018
“Can we afford to avoid the cost discussion?” National Patient Advocate Foundation, National webinar	2018
“Intervening on financial toxicity of cancer care” Medicine Grand Rounds, University of Austin Dell School of Medicine, Austin, TX	2018
“Intervening on financial toxicity of cancer care” Teen Cancer American, National Webinar	2018
“Value in oncology: From precision medicine to precision delivery” Beaumont Oncology Grand Rounds, Detroit, MI	2018
“Financial burden in cancer care: Where do we go from here?” ASTRO Annual Meeting Health Services Research Discussion, San Antonio, TX	2018
“Integrating cost into cancer therapy decision making” Virginia Oncology Associates New Developments in Oncology Conference, Norfolk, VA	2018
“Improving transparency and communication about costs” ASCO Palliative Care Symposium, San Diego, CA	2018

**Extramural Invited Oral Presentations – Local/Regional**

“Gastrointestinal Malignancy at ASCO 2008” Highlights from ASCO 2008, Cary, NC	2008
“Gastrointestinal Malignancy at ASCO 2012” Highlights from ASCO 2012, Cary, NC	2012
“Doc, I can’t afford it’: The financial toxicity of cancer care” Cancer Health Outcomes Conference, University of North Carolina, Chapel Hill, NC	2014
“First line treatment for metastatic colorectal cancer: Does it matter?” Duke Debates – Controversies in the Management of Gastrointestinal Cancers, Cary, NC	2014
“It’s time to have the talk: Addressing the financial toxicity of cancer care” Triangle Oncology Nursing Society Meeting, Durham, NC	2014
“The elephant in the room: How high cost is harming cancer care” Duke Cancer Network Annual Retreat, Durham, NC	2014
“The elephant in the room: How high cost is harming cancer care” North Carolina Oncology Pharmacists Association Meeting, Cary, NC	2014
“Can we afford cancer care?” Keynote Speaker, Annual Duke Cancer Review, Durham, NC	2015
“The value proposition in oncology” Grand Rounds, Cape Fear Valley Medical Center, Fayetteville, NC	2016
“Financial toxicity: A growing concern among cancer patients.” Patient Navigation in North Carolina Conference, Chapel Hill, NC	2016
“Financial toxicity in oncology” Triangle Oncology Nursing Society, Raleigh, NC	2016
“Financial toxicity of cancer care” AHEC Grand Rounds, Vidant, Tarboro, NC	2017
“Financial toxicity in young adult cancer patients.” Inaugural North Carolina Adolescent and Young Adult Oncology Symposium, Chapel Hill, NC	2018
“The financial toxicity of cancer care” University of North Carolina School of Medicine Prevention Program, Chapel Hill, NC	2018
“The financial toxicity of cancer care” University of North Carolina School of Public Health, Chapel Hill, NC	2018
“Healthcare Delivery Research.” 17th Annual Southeastern Research Retreat, Duck, NC	2018
“Can we afford to avoid the cost discussion?” University of North Carolina Medical Ethics Grand Rounds, Chapel Hill, NC	2018
“Value in oncology: From precision medicine to precision delivery” Duke Cancer Network Annual Oncology Review Keynote Lecture, Cary, NC	2018

**Intramural Invited Oral Presentations**

“Transdermal pain management.” Cancer Pain Symposium, Duke University Medical Center	2008
“How to treat metastatic colorectal cancer.” Hematology/Oncology Fellows conference, Duke University Medical Center	2008
“Metastatic cardiac tumors.” Department of Medicine Morbidity and Mortality Conference, Duke University Medical Center	2010
“Colorectal cancer: Staging and initial therapy.” Hematology/Oncology Fellows Conference, Duke University Medical Center	2010
“Perioperative treatment for rectal cancer.” Colorectal Cancer Tumor Board, Duke University Medical Center	2010

"Defining best supportive care in advanced cancer clinical trials." Palliative Care Conference, Duke Center for Palliative Care	2010
"How should we treat financial toxicity?" Hematology/Oncology Grand Rounds	2011
"Colorectal cancer." Hematology/Oncology Fellows Conference, Duke University Medical Center	2012
"Colorectal cancer screening and initial therapy." Internal Medicine Residents Noon Conference, Duke University Medical Center	2012
"Global cancer and cost of care" Global Cancer Research at Duke, for the Director of NCI Global Health visit to Duke Cancer Institute	2012
"Personalized Medicine: the right treatment for the right patient, but at what price?" Panelist, Duke MBA Health Care Conference	2013
"Financial burden and treatment decision-making: Does cost matter?" Duke Cancer Institute Cancer Control Program	2013
"It's time to have the talk: Including healthcare costs in palliative care?" Duke Palliative Care Conference	2014
"The Elephant in the room: Is it time to talk costs?" Duke Hematology/Oncology Grand Rounds	2014
"The Elephant in the room: Is it time to talk costs?" Duke Gastroenterology Research Conference	2014
"The financial toxicity of cancer care" Duke Government Relations Program, Duke Cancer Institute	2014
"Intervening on financial toxicity" Duke Cancer Institute, Health Services Research in Oncology Seminar	2015
"Value in Oncology." Duke Hematology/Oncology Grand Rounds	2015
"Value in Healthcare: Patients, providers, and politics." Duke Department of Radiology Grand Rounds	2016
"Perspectives from Oncology" Duke Clinical Research Institute Learning Lab	2016
"Healthcare Delivery Research at Duke Cancer Institute" Duke Hematology/Oncology Grand Rounds	2016
"Lemonade" William H. Kane Teaching Award Lecture, Duke Hematology/Oncology Grand Rounds	2016
"The value proposition in healthcare" Duke Division of Gastroenterology Grand Rounds	2016
"Resource allocation and patient decision-making." Duke Clinical Research Institute-BMS Seminar	2016
"End-of-Life communication." DCRI-Novartis LaCAN Heart Failure Program	2016
"Financial toxicity of cancer treatment." Duke Cancer Institute Board of Advisors Meeting	2016
"Patient financial assistance programs: Who do they really assist?" Duke Palliative Care Grand Rounds	2017
"Financial toxicity of cancer care." Duke Cancer Institute Melanoma Patient Conference	2017
"Resource allocation and patient decision-making." Duke Clinical Research Institute-BMS Seminar	2017
"Financial toxicity of cancer care." Duke Sanford School of Public Policy Seminar Series	2017
"The gorilla in our midst: Defining value in cancer care from patient and provider perspectives" Duke Cancer Institute Cancer Control and Population Science Seminar	2018
"A path to affordable cancer care" Palliative Care Innovations Conference, Duke University School of Medicine	2018

“Building a bridge to affordable cancer care” Duke University School of Medicine Clinical Research Day 2018

**Select Abstracts and Poster Presentations**

- “Characteristics and motivations of participants in a lung cancer screening study.” **Zafar Y**, Kleykamp B, Neu J, Buncher R, Shipley R, Jazieh AR, Howington J. American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2004
- “Preliminary results of a phase I study of bevacizumab (B) in combination with everolimus (E) in patients with advanced solid tumors.” **Zafar Y**, Bendell J, Lager J, Yu D, George D, Nixon A, Petros W, Beci R, Arrowood C, Hurwitz H. American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2006
- “Comorbidity, age and stage at diagnosis in colorectal cancer (CRC).” **Zafar Y**, Abernethy AP, Abbott DH, Herndon JE, Rowe K, Kolimaga J, Conner L, Patwardhan M, Grambow S, Provenzale D. American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2007
- “Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): a Cancer Outcomes Research & Surveillance Consortium (CanCORS) study.” **Zafar Y**, Granbow S, Abbott D, Schrag D, Kolimaga J, Weeks J, Provenzale D. American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2008
- “Electronic patient-reported data capture as the foundation of a learning healthcare system.” Abernethy AP, **Zafar SY**, Coeytaux R, Rowe K, Wheeler JL, Lyerly HK. American Society of Clinical Oncology Annual Meeting. (Poster presentation with oral discussion) 2009
- “Assessment of cancer registries (CR) in low- and middle-income countries (LMCs).” Zullig LL, Vanderberg S, Johnson D, Oneko O, Muiruri C, Ntabaye M, Abernethy AP, Bartlett JB, **Zafar SY**. 2012 American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2012
- “African cancer registries: A local issue of global significance.” Vanderberg S, **Zafar SY**, Zullig L, Johnson D, Oneko O, Muiruri C, Abernethy A, Ntabaye M, Bartlett J. African Organisation for Research and Training in Cancer Annual Meeting. Cairo, Egypt. (Oral presentation by Vanderberg S) 2011
- “Survival Among Metastatic Colorectal Cancer Patients Treated in a Randomized Controlled Trial Versus an Observational Cohort Study” **Y Zafar**, A Grothey, TS Bekaii-Saab, J Bendell, B Sherrill, L Bennett, Y Mun, M Sersch, D Dalal, HI Hurwitz. European Society of Medical Oncology Meeting, Vienna, Austria. (Poster presentation) 2012
- “Copayment assistance and adherence to prescription medication among cancer patients.” Zullig LL, Peppercorn J, Schrag D, Taylor D, Zhong, X, Samsa G, Abernethy A, **Zafar SY**. 2012 American Society of Clinical Oncology Quality Care Symposium. (Poster presentation) 2012
- “The financial burden of cancer care: Do patients know what to expect?” Chino F, Peppercorn JM, Tulskey JA, Ubel PA, Schrag D, Rushing D, Nicolla J, Altomare I, Samsa G, Abernethy AP, **Zafar SY**. American Society of Clinical Oncology Annual Meeting. (Poster presentation with oral discussion) 2013

- "Best supportive care (BSC) in clinical trials: Inconsistency in control arm design." Abernethy AP, Nipp RD, Wiebe LA, Currow DC, Cherny N, Strasser D, **Zafar SY**. American Society of Clinical Oncology Annual Meeting. (Poster presentation) 2013
- "A Qualitative Assessment of Sustainability of a Cancer Registry at a Tertiary Medical Center in Kilimanjaro, Tanzania." Zullig LL, Vanderburg SB, Muiruri C, Bartlett J, Olola O, **Zafar SY**. *African Organisation for Research & Training in Cancer*. Durban, South Africa; November 2013. (Poster) 2013
- "Patient-Oncologist Cost Communication, Financial Distress, and Medication Adherence." Bestvina C, Zullig L, Rushing C, Chino F, Samsa G, Altomare I, Tulskey J, Ubel P, Schrag D, Nicolla J, Abernethy A, Peppercorn J, **Zafar SY**. Abstract # 2. Presented at ASCO Quality Symposium, San Diego, CA. November 2, 2013. (Oral presentation) 2013
- "Can we identify patients at risk for discordance in preferred and actual role in cancer treatment decision-making?" Zullig LL, Rushing C, Chino F, Samsa G, Altomare I, Tulskey J, Ubel P, Nicolla J, Abernethy AP, Peppercorn J, **Zafar SY**. Poster: *American Society of Clinical Oncology Annual Meeting*. Chicago, IL; June 2014. 2014
- "Physician experience and attitudes toward addressing the costs of cancer care." Altomare I, Irwin B, **Zafar SY**, Houck K, Maloney B, Greenup R, Peppercorn J. *American Society of Clinical Oncology Annual Meeting*. Chicago, IL; June 2014. abst #6561 2014
- "Does cancer treatment-related financial distress worsen over time?" Van Nimwegen L, Rushing C, Chino F, Samsa G, Altomare I, Tulskey J, Ubel P, Nicolla J, Abernethy AP, Peppercorn J, **Zafar SY**. Poster. *American Society of Clinical Oncology Annual Meeting*. Chicago, IL; June 2014. 2014
- "Survival outcomes according to body mass index: results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer" **Zafar SY**, Kozloff M, Hubbard J, Van Cutsem E, Hermann F, Storm AJ, Gomez E, Revil C, Grothey A. Oral presentation. *ESMO World Congress on Gastrointestinal Cancer 2015*, Barcelona, Spain 2015
- "Health plan selection and out-of-pocket costs for cancer patients in the health insurance exchange" Gable C, Taylor DH, **Zafar SY**. Oral presentation. *American Society of Clinical Oncology Annual Meeting*. Chicago, IL; June 2016 2016
- "Empowering patients to self-identify financial assistance programs using an online application." Nicolla J, Friedman F, Manners I, **Zafar Y**. Abstract #4 ASCO Quality Symposium, Orlando, FL. March 2017. 2017

### **Duke Courses**

- "The global cancer burden: A false dichotomy?" Guest Lecturer for GLHLTH 701 Global Health Challenges, Masters in Global Health Program, Duke Global Health Institute 2011-2017
- "24-3-1: The global cancer imbalance." Guest Lecturer for GLHLTH 641 Global Health Challenges, Masters in Global Health Program, Duke Global Health Institute 2012-present

“Therapy for localized colorectal cancer” Hematology/Oncology Fellows’ Seminar	2015-present
“Financial burden of healthcare.” Guest Lecturer for HLTHMGMT 706 Seminars in Health Care, Masters in Business Administration Health Sector Management Program, Fuqua School of Business	2017-present
“Cost, coverage, and care: Impact of drug prices and insurance design on healthcare delivery” PUBPOL 393; Independent study in Trinity College and Sanford School of Public Policy	2017

### ***Mentoring***

#### **Advisees:**

Jessica Harris; MPP/MBA Candidate, Sanford School of Public Policy and Fuqua School of Business, Duke University	2011-2012
Leah Zullig; Faculty, Duke Department of Internal Medicine, Durham VA Sky Vanderberg; MD Candidate, Duke University School of Medicine	2011-present 2011-2014
Manisha Bhattacharya; MD/MBA Candidate, School of Medicine and Fuqua School of Business, Duke University	2011-2013
Christopher de Boer; MSc-GH Candidate, Duke Global Health Institute	2012-2014
Fumiko Chino; Medical student, Duke University School of Medicine	2012-present
Ryan Nipp, MD; Medicine resident, Duke University School of Medicine	2012-2015
Christine Bestvina, MD; Medicine resident, Duke University School of Medicine	2013-2014
Julian Xie; Undergraduate, Duke University	2013-2014
Lena Van Nimwegan; Medical student, Duke University School of Medicine	2013-2015
Amy Jones, MD; Medicine resident, Duke University School of Medicine	2014-2016
Rachel Greenup, MD; Assistant Professor of Surgery, Duke University School of Medicine	2016-present
Oluwadamilola (Lola) Fayanju, MD, MA, MPHS; Assistant Professor of Surgery, Duke University School of Medicine	2016-present
Caroline Sloan, MD; Medicine resident, Duke University School of Medicine	2016-present
Andrea Sitlinger, MD; Fellow, Hematology-Oncology, Duke University School of Medicine	2017-present
Laura Musselwhite, MD; Fellow, Hematology-Oncology, Duke University School of Medicine	2017-present
George Tran; Medical Student, Duke University School of Medicine	2017-present
Rishi Sachdev; Undergraduate, Duke University	2017-2018

#### **Thesis committees:**

Jessica Harrison, Master of Public Policy, Committee member	2012
Nixon Nyonzima, Master of Global Health, Committee member	2012
Christopher de Boer, Master of Global Health, Committee chair	2013
Junyang Wang, Master of Global Health, Committee member	2014

### ***Editorial activities***

<b>Editorial Board Member:</b> <i>Journal of Oncology Practice</i>	2014-present
--	--------------

**Ad Hoc Reviewer:** *JAMA, Journal of the National Cancer Institute, Journal of Clinical Oncology, Health Affairs, Cancer, British Journal of Cancer, Medical Care, The Oncologist, Journal of Oncology Practice, Journal of General Internal Medicine, Cancer Epidemiology, Biomarkers and Prevention, Journal of Pain and Symptom Management, The American Journal of Managed Care, Journal of Supportive Care in Cancer, Journal of Comparative Effectiveness Research, Journal of Medical Economics, North Carolina Medical Journal*

### **Conference leadership**

“Communication Skills Conference;” Co-director for monthly conference for hematology/oncology fellows	2012-present
“Controversies in the management of gastrointestinal malignancies: Bi-Annual Duke GI Debates” CME Course Co-director	2013-present
American Society of Clinical Oncology Quality Symposium: Planning Committee Member	2014-2017
“Disparities/Equity in Oncology Treatment and Prevention: Practice, Policy, and Cost Barriers and Solutions,” Eighth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved: Session Chair	2015

### **SELECT NATIONAL MEDIA COVERAGE**

“Out-of-Pocket Costs for Some Cancer Patients Top \$700 Monthly” <i>Wall Street Journal Health Blog.</i> <a href="http://on.wsj.com/161tYW3">http://on.wsj.com/161tYW3</a>	2011
“Cancer treatment costs can be prohibitive, even with insurance.” <i>Washington Post.</i> <a href="http://wapo.st/161tWxj">http://wapo.st/161tWxj</a>	2011
“Cancer costs put treatments out of reach for many.” <i>Reuters.</i> <a href="http://reut.rs/161tXRU">http://reut.rs/161tXRU</a>	2011
“Medical Debt: An Unspoken Side Effect of Cancer Care.” <i>Cure Magazine.</i> <a href="http://bit.ly/12KaNDc">http://bit.ly/12KaNDc</a>	2011
“Cancer Network Features Coverage of Financial Toxicity” <i>Wall Street Journal.</i> <a href="http://on.wsj.com/1aK90jK">http://on.wsj.com/1aK90jK</a>	2013
“Cancer Patients Often Shy Away From Talking About Costs” <i>US News &amp; World Report.</i> <a href="http://bit.ly/12K9DHS">http://bit.ly/12K9DHS</a>	2013
“Up For Discussion: Cost of Cancer Care Avoided Too Often” <i>NPR</i> <a href="http://n.pr/10XppeP">http://n.pr/10XppeP</a>	2013
“Life, Interrupted: The Cost of Cancer” <i>New York Times Well Blog</i> <a href="http://nyti.ms/12K9VOV">http://nyti.ms/12K9VOV</a>	2013
“Should doctors consider medical costs?” <i>Boston Globe</i> <a href="http://bit.ly/1k71dPT">http://bit.ly/1k71dPT</a>	2014
“Expensive drugs forcing cancer doctors to weigh price” <i>Bloomberg</i> <a href="http://bloom.bg/1oPahOK">http://bloom.bg/1oPahOK</a>	2014
“Cancer Treatment Costs Weigh Heavily on Patients, Study Finds” <i>US News &amp; World Report</i> <a href="http://t.usnews.com/Z50x4r">http://t.usnews.com/Z50x4r</a>	2014
“Obamacare's guaranteed health coverage changes lives in first year.” <i>LA Times</i> <a href="http://fw.to/EKk6nrS">http://fw.to/EKk6nrS</a>	2015
“Tackling the financial toll of cancer, one patient at a time.” <i>Washington Post</i> <a href="http://wpo.st/SVu_1">http://wpo.st/SVu_1</a>	2016

- “For working-age cancer survivors, debt and bankruptcy are common.” 2016  
*Reuters* <http://reut.rs/1OKSCol>
- “As drug costs soar, people delay or skip cancer treatments.” *NPR* 2017  
<https://n.pr/2mnAdSh>
- “Even insured cancer patients are overwhelmed by the cost of cancer care” 2017  
*Forbes* <http://bit.ly/2vvlko4>
- “Widowed early, a cancer doctor writes about the harm of medical debt” *NPR* 2017  
<http://n.pr/2vIFCeD>
- “Cancer takes financial toll, even with insurance” *US News & World Report* 2017  
<http://bit.ly/2vwj2VW>
- “Many cancer patients juggle care along with financial pain” *Associate Press* 2018  
<https://bit.ly/2s2o61a>